Clinical Trials Browser

Phase 3 × Cladribine × 90 days × Clear all

NCT06463587 2026-03-19

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

Phase 3 Recruiting

Myasthenia Gravis

NCT03926624 2026-01-22

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Phase 3 Terminated

Other hematologic neoplasm

Leukemia, Myeloid, Acute